CliffBio
small molecule

XELSTRYM

DEXTROAMPHETAMINE

Loss of exclusivityJanuary 2042latest FDA-listed patent expiry
CompanyNoven Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameXELSTRYM
Active ingredientDEXTROAMPHETAMINE
Strength9MG/9HR
Dosage formSYSTEM
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalMarch 2022
Marketing statusRX

Listed patents

PatentExpiresType
11559501January 2042product
9456993October 2033product
9474722October 2033product

More from Noven Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XELSTRYM patent cliff — loss of exclusivity January 2042 | CliffBio